Inozyme Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INZY research report →
Range $4 – $16
Price Chart
About the company
Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure.
- CEO
- Douglas A. Treco
- IPO
- 2020
- Employees
- 67
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on INZY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $258.25M
- P/E
- -2.47
- PEG
- 0.12
- P/S
- 0.00
- P/B
- 4.34
- EV/EBITDA
- -2.73
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -102.90%
- ROIC
- -99.36%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-104,030,000
- Net Income
- $-102,024,000-43.4%
- EPS
- $-1.62-18.2%
- OCF Growth
- -30.0%
- FCF Growth
- -29.6%
- 52W High
- $6.24
- 52W Low
- $0.72
- 50D MA
- $2.85
- 200D MA
- $2.79
- Beta
- 2.29
- RSI (14)
- 83
- Avg Volume
- 2.26M
No earnings-call transcripts are available for INZY yet.
- Free Float
- 67.2%
- Shares Outstanding
- 64.56M
- Float Shares
- 43.37M
of shares held by institutions
99 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 3.34M | ▲ 254.54K |
| Nuveen Asset Management, LLC | 250.23K | ▲ 47.50K |
Held by 1 ETFs
Biggest fund positions in INZY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 25 | Subramanian Sanjay | sell | 180,000 |
| Jul 1, 25 | Subramanian Sanjay | sell | 135,000 |
| Jul 1, 25 | Subramanian Sanjay | sell | 145,000 |
| Jul 1, 25 | Subramanian Sanjay | other | 39,701 |
| Jul 1, 25 | Subramanian Sanjay | sell | 38,500 |
| Jul 1, 25 | Winton Matthew | sell | 145,000 |
| Jul 1, 25 | Winton Matthew | other | 21,743 |
| Jul 1, 25 | Winton Matthew | sell | 41,500 |
| Jul 1, 25 | Bolte Axel | other | 423,926 |
| Jul 1, 25 | Bolte Axel | sell | 234,176 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INZY coverage
Recent articles, reports, and earnings notes.
No research on INZY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INZY report →BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401
seekingalpha.com · Aug 5
BioMarin Announces Completion of Acquisition of Inozyme
prnewswire.com · Jul 1
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
globenewswire.com · Jun 20
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY
businesswire.com · May 21
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc. - INZY
prnewswire.com · May 16
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHTR and INZY on Behalf of Shareholders
prnewswire.com · May 16
INZY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inozyme Pharma, Inc. Is Fair to Shareholders
businesswire.com · May 16
Shareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public Shareholders
businesswire.com · May 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.